A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The partnership initially will focus on cardiovascular and kidney diseases
Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
This marks the second indication for which gumokimab has gained NDA review acceptance
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
Subscribe To Our Newsletter & Stay Updated
